Background Peak oxygen uptake (pVO2) is a predictor of adverse cardiovascular outcomes, supporting cardiopulmonary exercise testing as a primary end point for assessing drug therapies in obstructive hypertrophic cardiomyopathy (oHCM). Characterizing changes in pVO2 that patients perceive as meaningful has not been determined. Methods Data from patients with symptomatic oHCM enrolled in SEQUOIA-HCM and MAPLE-HCM were pooled. Patients were randomized 1:1 to daily aficamten (5–20 mg) or placebo (SEQUOIA-HCM, n = 282), and 1:1 to aficamten (5–20mg) or metoprolol (50–200 mg) (MAPLE-HCM, n = 175).
The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy / Masri, A., Lewis, G.D., Barriales-Villa, R., Claggett, B.L., Coats, C.J., Elliott, P., Hagège, A., Kulac, I.J., Garcia-Pavia, P., Fifer, M.A., Meder, B., Olivotto, I., Nassif, M.A., Lakdawala, N.K., Owens, A.T., Heitner, S.B., Jacoby, D.L., Sohn, R., Kupfer, S., Malik, F.I., et al.. - In: JOURNAL OF CARDIAC FAILURE. - ISSN 1532-8414. - ELETTRONICO. - (2026), pp. 0-0. [10.1016/j.cardfail.2026.08.011]
The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Olivotto, Iacopo;
2026
Abstract
Background Peak oxygen uptake (pVO2) is a predictor of adverse cardiovascular outcomes, supporting cardiopulmonary exercise testing as a primary end point for assessing drug therapies in obstructive hypertrophic cardiomyopathy (oHCM). Characterizing changes in pVO2 that patients perceive as meaningful has not been determined. Methods Data from patients with symptomatic oHCM enrolled in SEQUOIA-HCM and MAPLE-HCM were pooled. Patients were randomized 1:1 to daily aficamten (5–20 mg) or placebo (SEQUOIA-HCM, n = 282), and 1:1 to aficamten (5–20mg) or metoprolol (50–200 mg) (MAPLE-HCM, n = 175).
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
